Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Follitropin alfa - Merck Serono

Drug Profile

Follitropin alfa - Merck Serono

Alternative Names: follitropin alfa injection - EMD; Follitropin-alpha; GONAL-f; GONAL-f RFF Redi-ject; Gonalef; Gonal–f® RFF Redi–ject®; Recombinant human follicle-stimulating hormone - Merck Serono; recombinant human follicle-stimulating hormone - Serono; rh-FSH; rhFSH - Merck Serono; rhFSH - Serono; SJ-0021

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Serono
  • Developer EMD Serono; Merck Serono; Nippon Shinyaku
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Chorionic gonadotropin stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Male infertility
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility; Male infertility

Most Recent Events

  • 07 Jul 2020 Launched for Female infertility (Combination therapy) in Hungary (SC)
  • 11 Feb 2020 Preregistration for Female infertility (Combination therapy) in Estonia, Latvia (SC) prior to February 2020
  • 11 Feb 2020 Registered for Female infertility (Combination therapy) in Latvia, Estonia (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top